262 related articles for article (PubMed ID: 23891559)
1. "Herbal incense": designer drug blends as cannabimimetics and their assessment by drug discrimination and other in vivo bioassays.
Järbe TU; Gifford RS
Life Sci; 2014 Feb; 97(1):64-71. PubMed ID: 23891559
[TBL] [Abstract][Full Text] [Related]
2. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?
Fantegrossi WE; Moran JH; Radominska-Pandya A; Prather PL
Life Sci; 2014 Feb; 97(1):45-54. PubMed ID: 24084047
[TBL] [Abstract][Full Text] [Related]
3. Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.
Marusich JA; Wiley JL; Lefever TW; Patel PR; Thomas BF
Neuropharmacology; 2018 May; 134(Pt A):73-81. PubMed ID: 29113898
[TBL] [Abstract][Full Text] [Related]
4. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.
Castaneto MS; Gorelick DA; Desrosiers NA; Hartman RL; Pirard S; Huestis MA
Drug Alcohol Depend; 2014 Nov; 144():12-41. PubMed ID: 25220897
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.
Wiley JL; Marusich JA; Lefever TW; Grabenauer M; Moore KN; Thomas BF
Neuropharmacology; 2013 Dec; 75():145-54. PubMed ID: 23916483
[TBL] [Abstract][Full Text] [Related]
6. Disruption of hippocampal synaptic transmission and long-term potentiation by psychoactive synthetic cannabinoid 'Spice' compounds: comparison with Δ
Hoffman AF; Lycas MD; Kaczmarzyk JR; Spivak CE; Baumann MH; Lupica CR
Addict Biol; 2017 Mar; 22(2):390-399. PubMed ID: 26732435
[TBL] [Abstract][Full Text] [Related]
7. Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences.
Thomas BF; Lefever TW; Cortes RA; Grabenauer M; Kovach AL; Cox AO; Patel PR; Pollard GT; Marusich JA; Kevin RC; Gamage TF; Wiley JL
J Pharmacol Exp Ther; 2017 Apr; 361(1):162-171. PubMed ID: 28087785
[TBL] [Abstract][Full Text] [Related]
8. Synthetic cannabinoids: analysis and metabolites.
Elsohly MA; Gul W; Wanas AS; Radwan MM
Life Sci; 2014 Feb; 97(1):78-90. PubMed ID: 24412391
[TBL] [Abstract][Full Text] [Related]
9. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
[TBL] [Abstract][Full Text] [Related]
10. Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids.
Wiley JL; Marusich JA; Huffman JW
Life Sci; 2014 Feb; 97(1):55-63. PubMed ID: 24071522
[TBL] [Abstract][Full Text] [Related]
11. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?
Seely KA; Prather PL; James LP; Moran JH
Mol Interv; 2011 Feb; 11(1):36-51. PubMed ID: 21441120
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity profiling of Cumyl-PEGACLONE variants at the CB
Janssens L; Cannaert A; Connolly MJ; Liu H; Stove CP
Drug Test Anal; 2020 Sep; 12(9):1336-1343. PubMed ID: 32490586
[TBL] [Abstract][Full Text] [Related]
14. [Drug discrimination properties and cytotoxicity of the cannabinoid receptor ligands].
Tomiyama K; Funada M
Nihon Arukoru Yakubutsu Igakkai Zasshi; 2012 Jun; 47(3):135-43. PubMed ID: 22894054
[TBL] [Abstract][Full Text] [Related]
15. Combination Chemistry: Structure-Activity Relationships of Novel Psychoactive Cannabinoids.
Wiley JL; Marusich JA; Thomas BF
Curr Top Behav Neurosci; 2017; 32():231-248. PubMed ID: 27753007
[TBL] [Abstract][Full Text] [Related]
16. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice.
Wiley JL; Marusich JA; Lefever TW; Antonazzo KR; Wallgren MT; Cortes RA; Patel PR; Grabenauer M; Moore KN; Thomas BF
J Pharmacol Exp Ther; 2015 Sep; 354(3):328-39. PubMed ID: 26105953
[TBL] [Abstract][Full Text] [Related]
17. Δ(9)-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids in mice and rats.
Gatch MB; Forster MJ
Psychopharmacology (Berl); 2016 May; 233(10):1901-10. PubMed ID: 26875756
[TBL] [Abstract][Full Text] [Related]
18. Structural characterization and pharmacological evaluation of the new synthetic cannabinoid CUMYL-PEGACLONE.
Angerer V; Mogler L; Steitz JP; Bisel P; Hess C; Schoeder CT; Müller CE; Huppertz LM; Westphal F; Schäper J; Auwärter V
Drug Test Anal; 2018 Mar; 10(3):597-603. PubMed ID: 28670781
[TBL] [Abstract][Full Text] [Related]
19. Spicing things up: synthetic cannabinoids.
Spaderna M; Addy PH; D'Souza DC
Psychopharmacology (Berl); 2013 Aug; 228(4):525-40. PubMed ID: 23836028
[TBL] [Abstract][Full Text] [Related]
20. Differentiation between low- and high-efficacy CB1 receptor agonists using a drug discrimination protocol for rats.
Järbe TU; LeMay BJ; Halikhedkar A; Wood J; Vadivel SK; Zvonok A; Makriyannis A
Psychopharmacology (Berl); 2014 Feb; 231(3):489-500. PubMed ID: 24005529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
